psychedelics investing Compass Pathways to Participate in Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026
psychedelics investing Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin
psychedelics investing Compass Pathways to Announce Second Quarter and First Half 2026 Financial Results on August 5, 2026
psychedelics investing Compass Pathways Announces Publication of Post-Hoc Analysis Demonstrating Distinction of COMP360 Trial Monitoring & Support from Psychotherapy
psychedelics investing Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile
psychedelics investing A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year
psychedelics investing Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 2026
psychedelics investing Compass Pathways to Participate in RBC Capital Markets Global Healthcare Conference on May 19-20, 2026
psychedelics investing Compass Pathways Announces First Quarter 2026 Financial Results and Business Highlights
psychedelics investing Compass Pathways to Announce First Quarter 2026 Financial Results on May 13, 2026
psychedelics investing Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher
psychedelics investing Compass Pathways Collaborates with Osmind to Advance Independent Clinic Readiness for Psychedelic Treatments
psychedelics investing Compass Pathways to Participate in Needham Virtual Psychedelics Forum on April 27, 2026
psychedelics investing Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments
America Can't Make Its Own Ammunition Metal. A Nevada Project Just Defined One of the Largest Domestic Sources
